Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Ovarian Neoplasms × Ashwagandha × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 1 Osteosarcoma 1

Interventions

Carboplatin 47 Paclitaxel 31 pembrolizumab 24 Cyclophosphamide 22 Nivolumab 14 Bevacizumab 14 Topotecan 12 Gemcitabine 12 liposomal doxorubicin 11 Filgrastim 11 Cisplatin 11 Peripheral Blood Stem Cell Transplantation 10 olaparib 9 fludarabine 9 durvalumab 7 aldesleukin 7 Oxaliplatin 6 Ipilimumab 6 Interleukin-2 6 Docetaxel 6 niraparib 5 epacadostat 5 cemiplimab 5 Ifosfamide 5 Fulvestrant 5 rucaparib 4 poly ICLC 4 pazopanib 4 avelumab 4 atezolizumab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05610735 2026-03-19

Combination Therapy for Recurrent Ovarian Cancer

University of Louisville

Phase 1/2 Recruiting

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡